- Home
- BFK vs RGNX Comparison
BFK vs RGNX Comparison
Compare BFK & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFK
- RGNX
- Stock Information
- Founded
- BFK N/A
- RGNX 2008
- Country
- BFK United States
- RGNX United States
- Employees
- BFK N/A
- RGNX N/A
- Industry
- BFK Finance Companies
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BFK Finance
- RGNX Health Care
- Exchange
- BFK Nasdaq
- RGNX Nasdaq
- Market Cap
- BFK 418.4M
- RGNX 451.1M
- IPO Year
- BFK N/A
- RGNX 2015
- Fundamental
- Price
- BFK $10.11
- RGNX $9.03
- Analyst Decision
- BFK
- RGNX Strong Buy
- Analyst Count
- BFK 0
- RGNX 8
- Target Price
- BFK N/A
- RGNX $28.50
- AVG Volume (30 Days)
- BFK 117.1K
- RGNX 502.6K
- Earning Date
- BFK 01-01-0001
- RGNX 11-05-2025
- Dividend Yield
- BFK 4.33%
- RGNX N/A
- EPS Growth
- BFK N/A
- RGNX N/A
- EPS
- BFK N/A
- RGNX N/A
- Revenue
- BFK N/A
- RGNX $155,782,000.00
- Revenue This Year
- BFK N/A
- RGNX $203.27
- Revenue Next Year
- BFK N/A
- RGNX $0.58
- P/E Ratio
- BFK N/A
- RGNX N/A
- Revenue Growth
- BFK N/A
- RGNX 74.95
- 52 Week Low
- BFK $8.55
- RGNX $5.04
- 52 Week High
- BFK $10.48
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- BFK 68.57
- RGNX 49.37
- Support Level
- BFK $9.91
- RGNX $8.82
- Resistance Level
- BFK $10.18
- RGNX $10.08
- Average True Range (ATR)
- BFK 0.10
- RGNX 0.54
- MACD
- BFK 0.03
- RGNX -0.05
- Stochastic Oscillator
- BFK 88.52
- RGNX 25.27
About BFK BlackRock Municipal Income Trust
Blackrock Municipal Income Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from regular U.S. federal income tax.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.